Effects of IL-6, IL-10 and TGF-β on the expression of survivin and apoptosis in nasopharyngeal carcinoma TW01 cells

Experimental Oncology

Volumn 34, Issue 2, 2012, Pages 85-89

  Poh, Y W ^a   Gan, S Y ^a   Tan, E L ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Apoptosis; Interleukin 10; Interleukin 6; Nasopharyngeal carcinoma; Survivin; Transforming growth factor (TGF )

Indexed keywords

CASPASE 3; INTERLEUKIN 10; INTERLEUKIN 6; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-10; INTERLEUKIN-6; NAPHTHOQUINONES; NASOPHARYNGEAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84865959960     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Cote R, Suster S, Weiss L, Weidner N. Modern Surgical Pathology (2 Volume Set). London: W B Saunders; 2003.
2. Curado MP, Edwards BK, Shin HR, et al., Eds. Cancer Incidence in Five Continents. No. 160. Lyon, France: IARC Press; 2007; p. 443.
3. Parkin DM, Whelan SL, Ferlay Thomas JO, et al., Eds. Cancer in Africa: epidemiology and prevention. No. 153. Lyon, France: IARC Press; 2003; p. 340.
4. Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. No. 155. Lyon, France: IARC Press: 2002; 212-309.
5. Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer 1993; 71: 2689-97. (Pubitemid 23100513)
6. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1765-77. (Pubitemid 44664247)
7. Huang YT, Sheen TS, Chen CL, et al. Cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin-1 in tumor and CD41 T cells. Cancer Res 1999; 59: 1599-605.
8. Tan EL, Selvaratnam G, Kananathan R, Sam CK. Quantification of Epstein - Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer. 2006; 6: 227-34.
9. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/ p16 (INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000; 19: 3225-34. (Pubitemid 30487409)
10. Tang F, Hu Z, Yin L, et al. Epstein - Barr virus lmp1 initiates cell proliferation and apoptosis inhibition via regulating expression of Survivin in nasopharyngeal carcinoma. Exp Oncol 2005; 27: 96-101.
11. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and Survivin-2B: two novel splice variants of the apoptosis inhibitor Survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-102. (Pubitemid 30035627)
12. Cheung CH, Chen HH, Kuo CC, et al. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 2009; 8: 43-57.
13. Sui L, Dong Y, Ohno M, et al. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002; 21: 315-20.
14. Morinaga S, Nakamura Y, Ishiwa N, et al. Expression of Survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 2004; 12: 1189-94.
15. Kawasaki H, Alteri DC, Lu CD, et al. Inhibition of apoptosis by Survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58: 5071-4. (Pubitemid 28521163)
16. Tanaka K, Iwamoto S, Gon G, et al. Expression of Survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-34. (Pubitemid 30064984)
17. Zaffaroni N, Pennati M, Colella G, et al. Expression of the anti-apoptotic gene Survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-12.
18. Tran J, Master Z, Yu JL, et al. A role for Survivin in chemo-resistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4349-54. (Pubitemid 34285988)
19. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecule Survivin and recurrence of bladder cancer. N Engl J Med 1999; 341: 452-3. (Pubitemid 29362524)
20. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-64. (Pubitemid 34161136)
21. Song C, Wang C, Huang L. Human neonatal neutrophils are resistant to apoptosis with lower Caspase-3 activity. J Esp Med 2011; 225: 59-63.
22. Rodel F, Hoffmann J, Grabenbauer GG, et al. High Survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002; 178: 426-35.
23. Hirai H, Roussel MF, Kato JY, et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-81.
24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
25. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005; 115: 2665-72. (Pubitemid 41434390)
26. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1321-16.
27. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-52.
28. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183-90. (Pubitemid 39372048)
29. Lai KN, Ho S, Leung JC, Tsao SY. Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma. Cancer 1991; 67: 2180-5.
30. Liu C-M, Ko JJ, Shun CT, et al. Soluble adhesion molecules and cytokines in tumor-associated tissue eosinophilia of nasopharyngeal carcinoma. Acta Oto-laryngologica 2001; 121: 534-8. (Pubitemid 32679414)
31. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502-12. (Pubitemid 41540626)
32. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16: 249-84. (Pubitemid 28102256)
33. Nakashima K, Wiese S, Yanagisawa M, et al. Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J Neurosci 1999; 19: 5429-34. (Pubitemid 29300208)
34. Kawano M, Hirano T, Martsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-5.
35. Interleukin-10 in cancer immunity. In: Cancer Immune Therapy: Experiences and Future Strategies. Stuhler G, Peter W, eds. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co.; 2002.
36. Alteri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999; 79: 1327-33.
37. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of Survivin. Proc Natl Acad Sci USA 2000; 97: 13103-7.
38. Shin S, Sung BJ, Cho YS. An anti-apoptotic protein human Survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40: 1117-23. (Pubitemid 32108606)
39. Kobayashi K, Hatano M, Otaki M. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 1999; 96: 1457-62. (Pubitemid 29098472)
40. Nakahara T, Masahiro T, Kinoyama I. YM155, a novel small-molecule Survivinsuppresant, induces regression of established human hormone-refractory prostate tumor xenographs. Cancer Res 2007; 67: 8014-21. (Pubitemid 47395135)